Anti-TNF therapy

Best Practice and Research: Clinical Rheumatology

Volumn 25, Issue 4, 2011, Pages 549-567

  Thalayasingam, Nishanthi ^a,b   Isaacs, John D ^a,c  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b Northern Deanery   (United Kingdom)

^c NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Anti TNF; Anti TNF switching; Biologic registries; Immunogenicity; Personalised medicine

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; ETANERCEPT; FC RECEPTOR; GOLIMUMAB; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN ANTIBODY; INFLIXIMAB; INTERLEUKIN 1BETA; LEFLUNOMIDE; LYMPHOTOXIN; METHOTREXATE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR;

APOPTOSIS; ARTICLE; BACTERIAL ARTHRITIS; BINDING AFFINITY; CANCER RISK; CELL ACTIVATION; CELL CYCLE ARREST; CELL PROLIFERATION; CENTRAL NERVOUS SYSTEM; CHOLESTEROL BLOOD LEVEL; CYTOKINE PRODUCTION; CYTOTOXICITY; DENDRITIC CELL; DISEASE COURSE; DISEASE DURATION; DNA POLYMORPHISM; DRUG BINDING; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG PACKAGING; DRUG STRUCTURE; DRUG TREATMENT FAILURE; FOLLOW UP; GENOMICS; GLYCOSYLATION; GRANULOMATOSIS; HEART INFARCTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOGENICITY; INFECTION RISK; KIDNEY CLEARANCE; LIMBIC SYSTEM; LIPID BLOOD LEVEL; MEMORY CELL; MONOTHERAPY; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PATENT; PATIENT COMPLIANCE; PERSONALIZED MEDICINE; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN DEGRADATION; QUALITY OF LIFE; REMISSION; RHEUMATOID ARTHRITIS; SEROLOGY; SIDE EFFECT; SIGNAL TRANSDUCTION; SKIN CANCER; SKIN INFECTION; SMOKING; SOFT TISSUE INFECTION; SOMATOSENSORY CORTEX; T LYMPHOCYTE; THALAMUS; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT;

EID: 82955237800     PISSN: 15216942     EISSN: 15321770     Source Type: Journal    
DOI: 10.1016/j.berh.2011.10.004     Document Type: Review

References (102)

1. D. Tracey, L. Klareskog, E.H. Sasso, J.G. Salfeld, and P.P. Tak Tumor necrosis factor antagonist mechanisms of action: a comprehensive review Pharmacology & Therapeutics 117 2 2008 244 279 Epub 2007/12/25
2. T. Saxne, M.A. Palladino Jr., D. Heinegard, N. Talal, and F.A. Wollheim Detection of tumor necrosis factor alpha but not tumor necrosis factor beta in rheumatoid arthritis synovial fluid and serum Arthritis and Rheumatism 31 8 1988 1041 1045 Epub 1988/08/01
3. J. Keffer, L. Probert, H. Cazlaris, S. Georgopoulos, E. Kaslaris, and D. Kioussis Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis The EMBO Journal 10 13 1991 4025 4031 Epub 1991/12/01 (Pubitemid 21905432)
4. M.J. Elliott, R.N. Maini, M. Feldmann, A. Long-Fox, P. Charles, and P. Katsikis Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha Arthritis and Rheumatism 36 12 1993 1681 1690 Epub 1993/12/01 (Pubitemid 23360007)
5. G. Eissner, W. Kolch, and P. Scheurich Ligands working as receptors: reverse signaling by members of the TNF superfamily enhance the plasticity of the immune system Cytokine & Growth Factor Reviews 15 5 2004 353 366 Epub 2004/09/29 (Pubitemid 39140699)
6. P.C. Taylor Pharmacology of TNF blockade in rheumatoid arthritis and other chronic inflammatory diseases Current Opinion in Pharmacology 10 3 2010 308 315 Epub 2010/02/23
7. R. Maini, E.W. St Clair, F. Breedveld, D. Furst, J. Kalden, and M. Weisman Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group Lancet 354 9194 1999 1932 1939 Epub 2000/01/06
8. Merck, Sharp, Dohme Ltd. Remicade, summary of product characteristics. 2011.
9. M.E. Weinblatt, E.C. Keystone, D.E. Furst, L.W. Moreland, M.H. Weisman, and C.A. Birbara Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial Arthritis and Rheumatism 48 1 2003 35 45 Epub 2003/01/16 (Pubitemid 36091645)
10. F.C. Breedveld, M.H. Weisman, A.F. Kavanaugh, S.B. Cohen, K. Pavelka, and R. van Vollenhoven The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment Arthritis and Rheumatism 54 1 2006 26 37 Epub 2005/12/31 (Pubitemid 43122183)
11. Abbott Laboratories Ltd. Humira, summary of product characteristics. 2011.
12. L.W. Moreland, M.H. Schiff, S.W. Baumgartner, E.A. Tindall, R.M. Fleischmann, and K.J. Bulpitt Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial Annals of Internal Medicine 130 6 1999 478 486 Epub 1999/03/13 (Pubitemid 29135800)
13. Wyeth Pharmaceuticals. Enbrel, summary of product characteristics. 2011.
14. E.C. Keystone, M.C. Genovese, L. Klareskog, E.C. Hsia, S.T. Hall, and P.C. Miranda Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study Annals of the Rheumatic Diseases 68 6 2009 789 796 Epub 2008/12/11
15. P. Emery, R. Fleischmann, D. van der Heijde, E.C. Keystone, M.C. Genovese, and P.G. Conaghan The effects of golimumab on radiographic progression in rheumatoid arthritis: results of randomized controlled studies of golimumab before methotrexate therapy and golimumab after methotrexate therapy Arthritis and Rheumatism 63 5 2011 1200 1210 Epub 2011/02/10
16. Merck, Sharp, Dohme Ltd. Simponi, summary of product characteristics. 2011.
17. P.J. Mease Certolizumab pegol in the treatment of rheumatoid arthritis: a comprehensive review of its clinical efficacy and safety Rheumatology (Oxford) 50 2 2011 261 270 Epub 2010/09/28
18. E. Keystone, D. Heijde, D. Mason Jr., R. Landewe, R.V. Vollenhoven, and B. Combe Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study Arthritis and Rheumatism 58 11 2008 3319 3329 Epub 2008/11/01
19. J. Smolen, R.B. Landewe, P. Mease, J. Brzezicki, D. Mason, and K. Luijtens Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial Annals of the Rheumatic Diseases 68 6 2009 797 804 Epub 2008/11/19
20. R. Fleischmann, J. Vencovsky, R.F. van Vollenhoven, D. Borenstein, J. Box, and G. Coteur Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study Annals of the Rheumatic Diseases 68 6 2009 805 811 Epub 2008/11/19
21. UCB Pharma Ltd. Cimzia, summary of product characteristics. 2011.
22. S. Kozlowski, J. Woodcock, K. Midthun, and R.B. Sherman Developing the nation's biosimilars program The New England Journal of Medicine 365 5 2011 385 388 Epub 2011/08/05
23. CHMP European medicines agency guideline on similar biological medicinal products London 2005
24. H. Schellekens Biosimilar therapeutics-what do we need to consider? NDT Plus 2 Suppl. 1 2009 i27 i36 Epub 2009/05/23
25. L. Klareskog, D. van der Heijde, J.P. de Jager, A. Gough, J. Kalden, and M. Malaise Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial Lancet 363 9410 2004 675 681 Epub 2004/03/06 (Pubitemid 38296553)
26. M.M. Soliman, D.M. Ashcroft, K.D. Watson, M. Lunt, D.P. Symmons, and K.L. Hyrich Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register Annals of the Rheumatic Diseases 70 4 2011 583 589 Epub 2011/02/19
27. M.L. Hetland, I.J. Christensen, U. Tarp, L. Dreyer, A. Hansen, and I.T. Hansen Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry Arthritis and Rheumatism 62 1 2010 22 32 Epub 2009/12/30
28. A. Zink, A. Strangfeld, M. Schneider, P. Herzer, F. Hierse, and M. Stoyanova-Scholz Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: comparison of patients according to their eligibility for major randomized clinical trials Arthritis and Rheumatism 54 11 2006 3399 3407 Epub 2006/11/01 (Pubitemid 44737150)
29. W.G. Dixon, K.L. Hyrich, K.D. Watson, M. Lunt, J. Galloway, and A. Ustianowski Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR) Annals of the Rheumatic Diseases 69 3 2010 522 528 Epub 2009/10/27
30. W.J. Sandborn, S.B. Hanauer, S. Katz, M. Safdi, D.G. Wolf, and R.D. Baerg Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial Gastroenterology 121 5 2001 1088 1094 Epub 2001/10/26 (Pubitemid 33022088)
31. Etanercept plus standard therapy for Wegener's granulomatosis The New England Journal of Medicine 352 4 2005 351 361 Epub 2005/01/28
32. R.P. Baughman, E.E. Lower, D.A. Bradley, L.A. Raymond, and A. Kaufman Etanercept for refractory ocular sarcoidosis: results of a double-blind randomized trial Chest 128 2 2005 1062-47. Epub 2005/08/16
33. J.P. Utz, A.H. Limper, S. Kalra, U. Specks, J.P. Scott, and Z. Vuk-Pavlovic Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis Chest 124 1 2003 177 185 Epub 2003/07/11 (Pubitemid 36851350)
34. J.H. Anolik, R. Ravikumar, J. Barnard, T. Owen, A. Almudevar, and E.C. Milner Cutting edge: anti-tumor necrosis factor therapy in rheumatoid arthritis inhibits memory B lymphocytes via effects on lymphoid germinal centers and follicular dendritic cell networks Journal of Immunology 180 2 2008 688 692 Epub 2008/01/08
35. S. Kirchner, E. Holler, S. Haffner, R. Andreesen, and G. Eissner Effect of different tumor necrosis factor (TNF) reactive agents on reverse signaling of membrane integrated TNF in monocytes Cytokine 28 2 2004 67 74 Epub 2004/09/24 (Pubitemid 39295687)
36. H. Mitoma, T. Horiuchi, N. Hatta, H. Tsukamoto, S. Harashima, and Y. Kikuchi Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-alpha Gastroenterology 128 2 2005 376 392 Epub 2005/02/03 (Pubitemid 40431090)
37. A. Nesbitt, G. Fossati, M. Bergin, P. Stephens, S. Stephens, and R. Foulkes Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents Inflammatory Bowel Diseases 13 11 2007 1323 1332 Epub 2007/07/20 (Pubitemid 350206841)
38. M.M. Herenius, R.M. Thurlings, C.A. Wijbrandts, R.J. Bennink, S.E. Dohmen, and C. Voermans Monocyte migration to the synovium in rheumatoid arthritis patients treated with adalimumab Annals of the Rheumatic Diseases 70 6 2011 1160 1162 Epub 2011/02/25
39. S. Radaev, and P. Sun Recognition of immunoglobulins by Fcgamma receptors Molecular Immunology 38 14 2002 1073 1083 Epub 2002/04/17
40. B. Scallon, A. Cai, N. Solowski, A. Rosenberg, X.Y. Song, and D. Shealy Binding and functional comparisons of two types of tumor necrosis factor antagonists The Journal of Pharmacology and Experimental Therapeutics 301 2 2002 418 426 Epub 2002/04/19 (Pubitemid 34429950)
41. Z. Kaymakcalan, C. Beam, and J.G. Salfeld Murine model for assessing adalimumab, infliximab and etanercept to prevent polyarthritis Annals of the Rheumatic Diseases 62 Suppl. 1 2003 136 137
42. R. Palframan, M. Airey, A. Moore, A. Vugler, and A. Nesbitt Use of biofluorescence imaging to compare the distribution of certolizumab pegol, adalimumab, and infliximab in the inflamed paws of mice with collagen-induced arthritis Journal of Immunological Methods 348 1-2 2009 36 41 Epub 2009/07/02
43. A. Hess, R. Axmann, J. Rech, S. Finzel, C. Heindl, and S. Kreitz Blockade of TNF-alpha rapidly inhibits pain responses in the central nervous system Proceedings of the National Academy of Sciences of the United States of America 108 9 2011 3731 3736 Epub 2011/01/20
44. J. Augustsson, M. Neovius, C. Cullinane-Carli, S. Eksborg, and R.F. van Vollenhoven Patients with rheumatoid arthritis treated with tumour necrosis factor antagonists increase their participation in the workforce: potential for significant long-term indirect cost gains (data from a population-based registry) Annals of the Rheumatic Diseases 69 1 2010 126 131 Epub 2009/05/28
45. T. Olofsson, M. Englund, T. Saxne, A. Joud, L.T. Jacobsson, and P. Geborek Decrease in sick leave among patients with rheumatoid arthritis in the first 12 months after start of treatment with tumour necrosis factor antagonists: a population-based controlled cohort study Annals of the Rheumatic Diseases 69 12 2010 2131 2136 Epub 2010/08/10
46. K. Bendtzen, P. Geborek, M. Svenson, L. Larsson, M.C. Kapetanovic, and T. Saxne Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab Arthritis and Rheumatism 54 12 2006 3782 3789 Epub 2006/11/30 (Pubitemid 44955878)
47. F. Baert, M. Noman, S. Vermeire, G. Van Assche, G. DH, and A. Carbonez Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease The New England Journal of Medicine 348 7 2003 601 608 Epub 2003/02/14 (Pubitemid 36204954)
48. G.M. Bartelds, C.L. Krieckaert, M.T. Nurmohamed, P.A. van Schouwenburg, W.F. Lems, and J.W. Twisk Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up JAMA: the Journal of the American Medical Association 305 14 2011 1460 1468 Epub 2011/04/14
49. D. Pascual-Salcedo, C. Plasencia, S. Ramiro, L. Nuno, G. Bonilla, and D. Nagore Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis Rheumatology (Oxford) 50 8 2011 1445 1452 Epub 2011/03/24
50. A. Finckh, J. Dudler, F. Wermelinger, A. Ciurea, D. Kyburz, and C. Gabay Influence of anti-infliximab antibodies and residual infliximab concentrations on the occurrence of acquired drug resistance to infliximab in rheumatoid arthritis patients Joint, Bone, Spine: Revue du Rhumatisme 77 4 2010 313 318 Epub 2010/05/18
51. L.A. Korswagen, G.M. Bartelds, C.L. Krieckaert, F. Turkstra, M.T. Nurmohamed, and D. van Schaardenburg Venous and arterial thromboembolic events in adalimumab-treated patients with antiadalimumab antibodies: a case series and cohort study Arthritis and Rheumatism 63 4 2011 877 883 Epub 2011/04/01
52. R. Davies, J.B. Galloway, K.D. Watson, M. Lunt, D.P. Symmons, and K.L. Hyrich Venous thrombotic events are not increased in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register Annals of the Rheumatic Diseases 2011 Epub 2011/07/26
53. R.N. Maini, F.C. Breedveld, J.R. Kalden, J.S. Smolen, D. Davis, and J.D. Macfarlane Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis Arthritis and Rheumatism 41 9 1998 1552 1563 Epub 1998/09/29 (Pubitemid 28459913)
54. S.M. Du Pan, S. Dehler, A. Ciurea, H.R. Ziswiler, C. Gabay, and A. Finckh Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis Arthritis and Rheumatism 61 5 2009 560 568 Epub 2009/05/01
55. D.E. Furst, N. Gaylis, V. Bray, E. Olech, D. Yocum, and J. Ritter Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study Annals of the Rheumatic Diseases 66 7 2007 893 899 Epub 2007/04/07 (Pubitemid 46999789)
56. S.N. Nikas, P.V. Voulgari, Y. Alamanos, C.G. Papadopoulos, A.I. Venetsanopoulou, and A.N. Georgiadis Efficacy and safety of switching from infliximab to adalimumab: a comparative controlled study Annals of the Rheumatic Diseases 65 2 2006 257 260 Epub 2005/06/25 (Pubitemid 43132005)
57. K.L. Hyrich, M. Lunt, K.D. Watson, D.P. Symmons, and A.J. Silman Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study Arthritis and Rheumatism 56 1 2007 13 20 Epub 2006/12/30 (Pubitemid 46106174)
58. J.S. Smolen, J. Kay, M.K. Doyle, R. Landewe, E.L. Matteson, and J. Wollenhaupt Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial Lancet 374 9685 2009 210 221 Epub 2009/06/30
59. J.A. Karlsson, L.E. Kristensen, M.C. Kapetanovic, A. Gulfe, T. Saxne, and P. Geborek Treatment response to a second or third TNF-inhibitor in RA: results from the South Swedish Arthritis Treatment Group Register Rheumatology (Oxford) 47 4 2008 507 513 Epub 2008/02/29
60. E. Solau-Gervais, N. Laxenaire, B. Cortet, S. Dubucquoi, B. Duquesnoy, and R.M. Flipo Lack of efficacy of a third tumour necrosis factor alpha antagonist after failure of a soluble receptor and a monoclonal antibody Rheumatology (Oxford) 45 9 2006 1121 1124 Epub 2006/03/03 (Pubitemid 44542100)
61. C.A. Wijbrandts, M.G. Dijkgraaf, M.C. Kraan, M. Vinkenoog, T.J. Smeets, and H. Dinant The clinical response to infliximab in rheumatoid arthritis is in part dependent on pretreatment tumour necrosis factor alpha expression in the synovium Annals of the Rheumatic Diseases 67 8 2008 1139 1144 Epub 2007/12/07
62. A. Jamnitski, G.M. Bartelds, M.T. Nurmohamed, P.A. van Schouwenburg, D. van Schaardenburg, and S.O. Stapel The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept Annals of the Rheumatic Diseases 70 2 2011 284 288 Epub 2010/11/12
63. A. Finckh, A. Ciurea, L. Brulhart, D. Kyburz, B. Moller, and S. Dehler B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents Arthritis and Rheumatism 56 5 2007 1417 1423 Epub 2007/05/01 (Pubitemid 46764068)
64. A. Finckh, A. Ciurea, L. Brulhart, B. Moller, U.A. Walker, and D. Courvoisier Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent? Annals of the Rheumatic Diseases 69 2 2010 387 393 Epub 2009/05/07
65. N.B. Klarenbeek, M. Guler-Yuksel, S.M. van der Kooij, K.H. Han, H.K. Ronday, and P.J. Kerstens The impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the BeSt study Annals of the Rheumatic Diseases 70 6 2011 1039 1046 Epub 2011/03/19
66. M.A. Quinn, P.G. Conaghan, P.J. O'Connor, Z. Karim, A. Greenstein, and A. Brown Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial Arthritis and Rheumatism 52 1 2005 27 35 Epub 2005/01/11 (Pubitemid 40129229)
67. Y. Tanaka, T. Takeuchi, T. Mimori, K. Saito, M. Nawata, and H. Kameda Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study Annals of the Rheumatic Diseases 69 7 2010 1286 1291 Epub 2010/04/03
68. J.A. Singh, G.A. Wells, R. Christensen, E. Tanjong Ghogomu, L. Maxwell, and J.K. Macdonald Adverse effects of biologics: a network meta-analysis and Cochrane overview Cochrane Database of Systematic Reviews 2 2011 CD008794 Epub 2011/02/18
69. J. Askling, E. Baecklund, F. Granath, P. Geborek, M. Fored, and C. Backlin Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register Annals of the Rheumatic Diseases 68 5 2009 648 653 Epub 2008/05/10
70. F. Wolfe, and K. Michaud Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients Arthritis and Rheumatism 50 6 2004 1740 1751 Epub 2004/06/10 (Pubitemid 38725085)
71. F.B. Pallavicini, R. Caporali, P. Sarzi-Puttini, F. Atzeni, C. Bazzani, and R. Gorla Tumour necrosis factor antagonist therapy and cancer development: analysis of the LORHEN registry Autoimmunity Reviews 9 3 2010 175 180 Epub 2009/08/04
72. J. Askling, C.M. Fored, L. Brandt, E. Baecklund, L. Bertilsson, and N. Feltelius Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists Annals of the Rheumatic Diseases 64 10 2005 1421 1426 Epub 2005/04/15 (Pubitemid 41623851)
73. A. Strangfeld, F. Hierse, R. Rau, G.R. Burmester, B. Krummel-Lorenz, and W. Demary Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT Arthritis Research & Therapy 12 1 2010 R5 Epub 2010/01/13
74. L. Carmona, L. Abasolo, M.A. Descalzo, B. Perez-Zafrilla, A. Sellas, and F. de Abajo Cancer in patients with rheumatic diseases exposed to TNF antagonists Seminars in Arthritis and Rheumatism 41 1 2011 71 80 Epub 2010/11/26
75. P. Raaschou, J.F. Simard, M. Neovius, and J. Askling Does cancer that occurs during or after anti-tumor necrosis factor therapy have a worse prognosis? A national assessment of overall and site-specific cancer survival in rheumatoid arthritis patients treated with biologic agents Arthritis and Rheumatism 63 7 2011 1812 1822 Epub 2011/02/10
76. W.G. Dixon, K.D. Watson, M. Lunt, L.K. Mercer, K.L. Hyrich, and D.P. Symmons Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the British Society for Rheumatology Biologics Register Arthritis Care & Research 62 6 2010 755 763 Epub 2010/06/11
77. F. Balkwill Tumour necrosis factor and cancer Nature Reviews Cancer 9 5 2009 361 371 Epub 2009/04/04
78. W.G. Dixon, K. Watson, M. Lunt, K.L. Hyrich, A.J. Silman, and D.P. Symmons Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register Arthritis and Rheumatism 54 8 2006 2368 2376 Epub 2006/07/27 (Pubitemid 44204996)
79. J.B. Galloway, K.L. Hyrich, L.K. Mercer, W.G. Dixon, A.P. Ustianowski, and M. Helbert Risk of septic arthritis in patients with rheumatoid arthritis and the effect of anti-TNF therapy: results from the British Society for Rheumatology Biologics Register Annals of the Rheumatic Diseases 2011 Epub 2011/07/26
80. J. Listing, A. Strangfeld, S. Kary, R. Rau, U. von Hinueber, and M. Stoyanova-Scholz Infections in patients with rheumatoid arthritis treated with biologic agents Arthritis and Rheumatism 52 11 2005 3403 3412 Epub 2005/10/29 (Pubitemid 41612206)
81. J.B. Galloway, K.L. Hyrich, L.K. Mercer, W.G. Dixon, B. Fu, and A.P. Ustianowski Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly Rheumatology (Oxford) 50 1 2011 124 131 Epub 2010/08/03
82. J. Askling, C.M. Fored, L. Brandt, E. Baecklund, L. Bertilsson, and N. Feltelius Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists Annals of the Rheumatic Diseases 66 10 2007 1339 1344 Epub 2007/01/31 (Pubitemid 47492478)
83. A. Strangfeld, M. Eveslage, M. Schneider, H.J. Bergerhausen, T. Klopsch, and A. Zink Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient? Annals of the Rheumatic Diseases 2011 Epub 2011/07/28
84. J.D. Greenberg, G. Reed, J.M. Kremer, E. Tindall, A. Kavanaugh, and C. Zheng Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry Annals of the Rheumatic Diseases 69 2 2010 380 386 Epub 2009/04/11
85. X. Mariette, J.E. Gottenberg, P. Ravaud, and B. Combe Registries in rheumatoid arthritis and autoimmune diseases: data from the French registries Rheumatology (Oxford) 50 1 2011 222 229 Epub 2010/12/15
86. D. Salmon-Ceron, F. Tubach, O. Lortholary, O. Chosidow, S. Bretagne, and N. Nicolas Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry Annals of the Rheumatic Diseases 70 4 2011 616 623 Epub 2010/12/24
87. A.M. van Sijl, M.J. Peters, D.L. Knol, R.H. de Vet, N. Sattar, and B.A. Dijkmans The effect of TNF-alpha blocking therapy on lipid levels in rheumatoid arthritis: a meta-analysis Seminars in Arthritis and Rheumatism 2011 Epub 2011/06/15
88. I.C. van Eijk, M.K. de Vries, J.H. Levels, M.J. Peters, E.E. Huizer, and B.A. Dijkmans Improvement of lipid profile is accompanied by atheroprotective alterations in high-density lipoprotein composition upon tumor necrosis factor blockade: a prospective cohort study in ankylosing spondylitis Arthritis and Rheumatism 60 5 2009 1324 1330 Epub 2009/05/01
89. W.G. Dixon, K.D. Watson, M. Lunt, K.L. Hyrich, A.J. Silman, and D.P. Symmons Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register Arthritis and Rheumatism 56 9 2007 2905 2912 Epub 2007/09/01 (Pubitemid 47502736)
90. L.T. Jacobsson, C. Turesson, A. Gulfe, M.C. Kapetanovic, I.F. Petersson, and T. Saxne Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis Journal of Rheumatology 32 7 2005 1213 1218 Epub 2005/07/05 (Pubitemid 40995372)
91. L.T. Jacobsson, C. Turesson, J.A. Nilsson, I.F. Petersson, E. Lindqvist, and T. Saxne Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis Annals of the Rheumatic Diseases 66 5 2007 670 675 Epub 2006/12/13 (Pubitemid 46707138)
92. M. Lunt, K.D. Watson, W.G. Dixon, D.P. Symmons, and K.L. Hyrich No evidence of association between anti-tumor necrosis factor treatment and mortality in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register Arthritis and Rheumatism 62 11 2010 3145 3153 Epub 2010/07/28
93. J. Listing, A. Strangfeld, J. Kekow, M. Schneider, A. Kapelle, and S. Wassenberg Does tumor necrosis factor alpha inhibition promote or prevent heart failure in patients with rheumatoid arthritis? Arthritis and Rheumatism 58 3 2008 667 677 Epub 2008/03/04 (Pubitemid 351364864)
94. J.D. Isaacs, and G. Ferraccioli The need for personalised medicine for rheumatoid arthritis Annals of the Rheumatic Diseases 70 1 2011 4 7 Epub 2010/11/12
95. L.E. Kristensen, M.C. Kapetanovic, A. Gulfe, M. Soderlin, T. Saxne, and P. Geborek Predictors of response to anti-TNF therapy according to ACR and EULAR criteria in patients with established RA: results from the South Swedish Arthritis Treatment Group Register Rheumatology (Oxford) 47 4 2008 495 499 Epub 2008/03/05
96. K.L. Hyrich, K.D. Watson, A.J. Silman, and D.P. Symmons Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register Rheumatology (Oxford) 45 12 2006 1558 1565 Epub 2006/05/18 (Pubitemid 44817065)
97. R. Klaasen, C.A. Wijbrandts, D.M. Gerlag, and P.P. Tak Body mass index and clinical response to infliximab in rheumatoid arthritis Arthritis and Rheumatism 63 2 2011 359 364 Epub 2011/02/01
98. C. Potter, K.L. Hyrich, A. Tracey, M. Lunt, D. Plant, and D.P. Symmons Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis Annals of the Rheumatic Diseases 68 1 2009 69 74 Epub 2008/04/01
99. L. Mancarella, F. Bobbio-Pallavicini, F. Ceccarelli, P.C. Falappone, A. Ferrante, and D. Malesci Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-alpha blockers: the GISEA study Journal of Rheumatology 34 8 2007 1670 1673 Epub 2007/07/06 (Pubitemid 47267608)
100. R. Klaasen, T. Cantaert, C.A. Wijbrandts, C. Teitsma, D.M. Gerlag, and T.A. Out The value of rheumatoid factor and anti-citrullinated protein antibodies as predictors of response to infliximab in rheumatoid arthritis: an exploratory study Rheumatology (Oxford) 50 8 2011 1487 1493 Epub 2011/04/02
101. W. Hueber, B.H. Tomooka, F. Batliwalla, W. Li, P.A. Monach, and R.J. Tibshirani Blood autoantibody and cytokine profiles predict response to anti-tumor necrosis factor therapy in rheumatoid arthritis Arthritis Research & Therapy 11 3 2009 R76 Epub 2009/05/23
102. B. Stuhlmuller, T. Haupl, M.M. Hernandez, A. Grutzkau, R.J. Kuban, and N. Tandon CD11c as a transcriptional biomarker to predict response to anti-TNF monotherapy with adalimumab in patients with rheumatoid arthritis Clinical Pharmacology and Therapeutics 87 3 2010 311 321 Epub 2009/12/25